Imtesty,

Yes, the presentations at ESC on the REVEAL (CETP inhibitor anacetrapib) and the CANTOS (anti-inflammatory Canakinumab antibody) cardiovascular outcomes trials will be very interesting. So far only top-line data has been released for these two trials. Although we know that these two trials met their primary endpoints for reducing MACE, we won't know the magnitude of the effect until the ESC presentatons. Merck's comments in the news release of top-line REVEAL data conveyed some doubt as to whether they were going to pursue filing an NDA for anacetrapib. We will know more of the story soon enough. 

BearDownAZ